<DOC>
	<DOCNO>NCT01764022</DOCNO>
	<brief_summary>BCD-022-02 double-blind randomize clinical trial compare efficacy BCD-022 ( INN : trastuzumab ) paclitaxel Herceptin paclitaxel HER2-positive metastatic breast cancer pharmacokinetics substudy . The purpose study demonstrate non-inferiority efficacy safety BCD-022 compare Herceptin . Also study include pharmacokinetics assessment .</brief_summary>
	<brief_title>A Safety Efficacy Study BCD-022 With Paclitaxel Compared Herceptin With Paclitaxel HER2-Positive Metastatic Breast Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Written inform consent ability follow Protocol procedure ; Age 18 year 75 year inclusive ; Female gender ; Histologically confirm breast cancer ( BC ) ; Metastatic BC ( stage IV accord TNM classification version 6 ) ; Grade 3+ HER2 overexpression confirm immunohistochemical ( IHC ) stain grade 2+ HER2 overexpression accompany HER2 gene amplification confirm fluorescent hybridization situ ( FISH ) ; Documented result oestrogen progesterone receptor expression analysis ; Eastern Cooperative Oncology Group ( ECOG ) status 0 , 1 2 , increase within 2 week prior randomization ; Life expectancy 20 week moment randomization ; Presence least 1 tumour size le 1 cm ( reveal compute tomography ( CT ) slice thickness 5 mm ) . Patients bone metastasis measurable tumour eligible trial ; Patients childbearing potential must implement reliable contraceptive measure study treatment , start 4 week prior inclusion trial 6 month last administration study drug . Previous anticancer therapy metastatic BC , include cytotoxic chemotherapy , previous anticancer therapy signal transduction inhibitor ( e.g . lapatinib ) , biological drug ( e.g . trastuzumab , bevacizumab ) , experimental ( approved BC therapy ) anticancer drug . Any previous hormonal therapy allow ; Disease progression within 6 month adjuvant and/or neoadjuvant anti BC therapy ; Surgery , radiation therapy , use experimental medication within 4 week ( 28 day ) prior randomization ; Hypersensitivity paclitaxel medication contain polyoxyethylated castor oil , hypersensitivity dexamethasone , diphenhydramine , ranitidine/cimetidine , recombinant murine protein , contrast agent excipients study medication ; BC metastases central nervous system , progress clinically manifest ( e.g . cerebral oedema , spinal cord injury ) , exception nonprogressing metastasis require treatment glucocorticosteroids and/or anticonvulsant within 4 week prior randomization ; Cardiovascular system pathology ( congestive heart failure ( CHF ) stage IIIIV accord New York Heart Association ( NYHA ) classification , unstable angina pectoris , myocardial infarction ) within 12 month prior randomization ; Uncontrolled hypertension comprise case arterial hypertension decrease blood pressure could achieve despite treatment combination 3 antihypertensive drug include one diuretic nonmedicamental correction method ( low salt diet , physical exercise ) ; Left ventricular ejection fraction &lt; 50 % accord electrocardiography ; Neutrophils ≤1500/mm3 ; Platelets ≤100 000/mm3 ; Hemoglobin ≤90 g/L ; Creatinine level ≥ 1.5 × upper limit normal ( ULN ) ; Bilirubin level ≥ 1.5 × ULN ; Asparagine transferase ( AST ) alanine transferase ( ALT ) level ≥ 2.5 × ULN ( 5 × ULN patient liver metastasis ) ; Alkaline phosphatase level ≥ 5 × ULN ; Pregnancy lactation ; Any concomitant cancer include contralateral breast cancer reveal within 5 year prior screen , except curatively treat intraductal carcinoma situ , curatively treated cervical carcinoma situ curatively treat basal cell squamous cell carcinoma ; Conditions limit patient 's adherence protocol requirement ( dementia , neurologic psychiatric disorder , drug addiction , alcoholism others ) ; Stage IIIV neuropathy accord Common Terminology Criteria Adverse Events ( CTCAE ) v.4.0 ; Concomitant participation clinical trial , previous participation clinical trial within 30 day enter trial , previous participation trial ; Acute active chronic infection ; Hepatitis C virus , hepatitis B virus , HIV syphilis infection ; Obstacles intravenous administration study drug</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>trastuzumab</keyword>
</DOC>